Poolbeg Pharma had received formal notification of the grant for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome patent application from the Canadian patent office. This represents the second national grant within Poolbeg's cancer immunotherapy-induced CRS patent family, following the grant by IP Australia announced in March 2026, and marks a further important milestone for the Company. This patent covers the use of any p38 MAPK inhibitor, including POLB 001, for the prevention of cancer immunotherapy-induced CRS, and is underpinned by proprietary data generated by Poolbeg.
Poolbeg filed its initial oncology patent applications in the UK in January 2023 before entering the international Patent Cooperation Treaty system in January 2024. This new patent grant was accelerated through the Patent Prosecution Highway, which enables expedited examination in participating countries where a favourable ruling has already been secured in another participating jurisdiction. The Company's IP portfolio now spans both cancer immunotherapy-induced CRS and severe influenza across multiple jurisdictions, and Poolbeg continues to pursue protection in further territories.
This grant further strengthens the Company's robust intellectual property portfolio, enhancing POLB 001's future value and appeal to potential partners.
